Related Experiment Videos
Novel biomarkers in chronic heart failure
Tariq Ahmad1, Mona Fiuzat, G Michael Felker
1Division of Cardiology, Duke University School of Medicine, 2400 Pratt Street, Durham, NC 27705, USA. ariq.ahmad@duke.edu
Nature Reviews. Cardiology
|March 28, 2012
Summary
Emerging molecular biomarkers offer new insights into chronic heart failure (HF) pathophysiology. These novel markers may improve prediction of adverse outcomes and guide personalized treatment strategies for heart failure patients.
Area of Science:
- Biomedical science
- Cardiology
- Molecular medicine
Background:
- Chronic heart failure (HF) understanding has evolved from hemodynamics to complex molecular pathways.
- Current HF assessment and treatment increasingly focus on modifying maladaptive molecular processes.
Purpose of the Study:
- To review emerging molecular biomarkers for chronic heart failure (HF).
- To explore their potential in predicting outcomes, identifying drug targets, and assessing therapeutic efficacy.
- To discuss the role of these biomarkers in a multimarker strategy for improved HF patient care.
Main Methods:
- Review of existing literature on molecular biomarkers in chronic heart failure.
- Analysis of properties, clinical data, and potential applications of emerging biomarkers.
- Discussion of traditional biomarkers (cardiac troponin, natriuretic peptides, C-reactive protein) and their established roles.
Main Results:
- Emerging biomarkers offer unique insights into biomechanical stretch, inflammation, ventricular remodeling, myocardial injury, and renal dysfunction in chronic HF.
- Traditional biomarkers have established clinical applications but emerging ones promise enhanced predictive and therapeutic value.
Conclusions:
- Molecular biomarkers are crucial for understanding chronic HF pathophysiology.
- Emerging biomarkers hold significant potential for improving patient outcomes and guiding treatment strategies.
- A multimarker approach may lead to more effective future management of chronic heart failure.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:26Heart Failure III: Clinical Manifestations
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...